• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Spain-Based Grifols Opens North Fractionation Facility in Clayton, North Carolina

Grifols, a Spain-based leader in the production of plasma-derived medicines used to treat rare and chronic diseases, opened its state-of-the-art North Fractionation Facility in Clayton, North Carolina, where production capacity of plasma will almost double to approximately 6 million liters annually.

Company officials said $370 million has been invested in NFF at its Clayton facility. In addition, new investments are planned to expand and increase Grifols' production facilities in both Spain and the United States. NFF will be fully operational in 2015 with over 200 employees. Grifols is the largest private employer in Johnston County, N.C. with 1,650 employees and a total of 2,300 statewide, including a corporate office in Research Triangle Park, North Carolina.

Grifols also has a corporate office and manufacturing facilities in Los Angeles, and testing labs in San Marcos and Austin, Texas. Additionally, the company has manufacturing facilities in San Francisco, producing antigens for immunological diagnostics, as well as the Grifols Academy of Plasmapheresis, a world-class education and training facility headquartered in Glendale, Arizona.

A substantial portion of its future investment plan will go towards the expansion of the albumin purification plants in Los Angeles and Clayton, North Carolina, and also towards a new warehouse at Clayton´s complex.

"As a leading healthcare company, one of Grifols' main goals since being founded in the 1940's has been to advance the plasma industry. Today, I take great pride in our pioneering spirit that has allowed us to build the world's largest and one of the most innovative plants producing plasma medicines. The donors who make our life-saving therapies possible, along with all Grifols employees, share my passion for the patients that we continue to serve," said Victor Grifols, President/CEO of Grifols.

“Choosing North Carolina for this facility is not a coincidence by any means. The US has always represented one of our most important markets, both past and present. Our investment of more than $7 billion since 2001 in this country demonstrates our long-term commitment to growth,” Grifols said.

"It is my pleasure to congratulate Grifols on the grand opening of its new plasma fractionation facility in Clayton," said Congressman Mike McIntyre. "This state-of-the-art plant is the largest of its kind in the world and represents a strong $370 million investment in Johnston County. The 200 employees who will work at the facility when fully operational will help ensure the availability of life-saving plasma-derived medicines for patients around the world. Grifols' 2,300 employees across North Carolina are a testament to the company's well-established commitment to our state."

The company said since 2001, it has invested more than $7 billion in the United States, including both capital expenditures and strategic acquisitions that have resulted in the company accounting for approximately 20 percent of the global plasma therapies market, in addition to leading other complementary business areas, such as transfusion medicine.


Exclusive Research